- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
CI Galaxy Bitcoin ETF
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Marina Biotech acquired the DyrctAxess technology platform from Symplmed Pharmaceuticals.
Marina Biotech (OTCQB:MRNA) acquired the DyrctAxess technology platform from Symplmed Pharmaceuticals.
As quoted in the press release:
DyrctAxess™ offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to help achieve optimal care. The secure, web-based, HIPAA-compliant platform provides:
- Direct fulfillment of physician prescriptions at a fixed cost to patients
- Easy prescription, tracking and refill management via mobile applications (iPhone and Android)
- Real-time monitoring and communications between patients and physicians
- Complete database capture of insurance reimbursement and transparency of co-pay and coverage positions
- Automatic patient reminders and refills
- Enhanced security with 128 bit SSL
Prestalia® will continue to be marketed using DyrctAxess™, which drove strong compliance and patient engagement when developed by Symplmed. Prestalia® is currently protected by two patents listed in the U.S. Food and Drug Administration’s (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The two Prestalia patents (6696481 and 7846961) offer product exclusivity until 2029.
Click here to read the full press release.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.